medicine-news-1/harrison-city-rocks-21-set-for-august-15--music-festival-to-benefit-cardiac-research-at-childrens-hospital-of-pittsburgh-53340-1/;/a><br

Breaking Biology Technology:Sangart, Inc. Receives European Orphan Drug Designation for the Use of MP4CO in Patients With Sickle Cell Disease 2 Sangart, Inc. Receives European Orphan Drug Designation for the Use of MP4CO in Patients With Sickle Cell Disease 3 MEDINA Scientists Select Genedata Screener for Lead Discovery from Natural Products 2 MEDINA Scientists Select Genedata Screener for Lead Discovery from Natural Products 3 MEDINA Scientists Select Genedata Screener for Lead Discovery from Natural Products 4 BioMed Realty Announces Results of Tender Offer for its Exchangeable Notes 2 BioMed Realty Announces Results of Tender Offer for its Exchangeable Notes 3 Waters Ships First Units of SYNAPT G2 Mass Spectrometer 2

[0] Sangart, Inc. Receives European Orphan Drug Designation for the Use of MP4CO in Patients With Sickle Cell Disease [0] MEDINA Scientists Select Genedata Screener for Lead Discovery from Natural Products [0] BioMed Realty Announces Results of Tender Offer for its Exchangeable Notes [0] Waters Ships First Units of SYNAPT G2 Mass Spectrometer

Breaking Medicine Technology:China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 2 China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 3 China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 4 China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 5 China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 6 China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 7 China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 8 OrBIT Study Long Term Results Show Sustained Therapeutic Effect of Percutaneous Tibial Nerve Stimulation at 12 Months 2 OrBIT Study Long Term Results Show Sustained Therapeutic Effect of Percutaneous Tibial Nerve Stimulation at 12 Months 3 OrBIT Study Long Term Results Show Sustained Therapeutic Effect of Percutaneous Tibial Nerve Stimulation at 12 Months 4 Brain difference in psychopaths identified 9468 1 Brain difference in psychopaths identified 9468 2 Ferring Pharmaceuticals Announces Trade Name FIRMAGON 28R 29 28degarelix for injection 29 for Advanced Prostate Cancer Treatment 53625 1 Ferring Pharmaceuticals Announces Trade Name FIRMAGON 28R 29 28degarelix for injection 29 for Advanced Prostate Cancer Treatment 53625 2 Ferring Pharmaceuticals Announces Trade Name FIRMAGON 28R 29 28degarelix for injection 29 for Advanced Prostate Cancer Treatment 53625 3 Ferring Pharmaceuticals Announces Trade Name FIRMAGON 28R 29 28degarelix for injection 29 for Advanced Prostate Cancer Treatment 53625 4 Office of National Drug Control Policy Taps RIESTER creative for Use in National Anti Meth Campaign 53622 1 Office of National Drug Control Policy Taps RIESTER creative for Use in National Anti Meth Campaign 53622 2

[0] China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 [0] Regeneron Announces Presentation at the Deutsche Bank 2009 Biotech Boston Confab [0] OrBIT Study Long Term Results Show Sustained Therapeutic Effect of Percutaneous Tibial Nerve Stimulation at 12 Months